The Green Cross Corporation

Medigenebio Corporation

Jong Mun Son

Yong-Chul Kim

Jinwook Seo

Thong-Gyu Jin

Sang Hoon Paik

Yo Kyung Chung

Yong Woon Choi

Yoo Chang Park

A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.

Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE&#xae; and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.

Growing community of inventors

Yongin-si, South Korea

Jong Mun Son